



NEWS RELEASE

Extraordinary General Shareholders' Meeting

IRVINE, CA, and HERSTAL, BELGIUM, 23 June 2014 –MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, held its Extraordinary General Meeting of shareholders in Zaventem today. The shareholders approved all agenda items of the Extraordinary General Meeting of shareholders.

About MDxHealth®

MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain, bladder and lung cancers. For more information visit www.mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

For more information:

Dr Jan Groen, CEO

Mike Sinclair

Len Hall

MDxHealth

Halsin Partners

Allen & Caron, Inc

US : +1 949 812 6979

UK: +44 20 7318 2955

US: +1 949 474 4300

BE: +32 4 364 20 70

Cell: +44 7968 022075

info@mdxhealth.com

msinclair@halsin.com

len@allencaron.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.